Trial reportBMC musculoskeletal disorders2025
Time-dependent growth factor kinetics, platelet concentration, and clinical response following platelet-rich plasma versus saline in chronic tenosynovitis: a randomized controlled trial.
Trial report in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet-rich plasma (PRP) therapy is utilized for chronic tenosynovitis to reduce inflammation and promote tendon sheath repair. This study compared the temporal kinetics of PRP-derived growth factors with clinical outcomes of PRP versus saline injection over 3 months.
methodsIn a randomized controlled trial, 200 patients with chronic tenosynovitis were assigned to non-activated PRP (n = 100) or saline (n = 100) tendon sheath injection. PRP group blood samples were collected at 1 h, 8 h, Days 1, 3, 7, 14, and 1 month post-injection; both groups had clinical and ultrasound assessments at 1 and 3 months. Serum VEGF, PDGF-AB, EGF, and TGF-β were quantified via ELISA, with platelet counts analyzed. Pain (VAS), function (WOMAC, DASH), and tendon sheath thickness were evaluated. Repeated-measures ANOVA and t-tests assessed changes.
resultsIn the PRP group, non-activated PRP achieved a platelet concentration of 1030 ± 130 × 10³/µL (4.5× baseline), and biomarkers varied significantly (p < 0.001). VEGF peaked at Day 14 (285.44 ± 50.0 pg/mL), sustained at 260.0 ± 45.0 pg/mL (1 month). PDGF-AB peaked at 8 h (1253.28 ± 160.0 pg/mL), declining to 300.0 ± 90.0 pg/mL (1 month). EGF peaked at Day 7 (451.84 ± 75.0 pg/mL), returning to 380.0 ± 75.0 pg/mL (1 month). TGF-β exhibited plateau kinetics without a distinct peak, stabilizing at 8.50 ± 1.80 ng/mL (1 month). PRP outperformed saline in pain (- 50.0 mm vs. -31.0 mm), function (QuickDASH - 35.0 vs. -21.0), and sheath thickness reduction (- 0.9 mm vs. -0.4 mm) at 3 months (all p < 0.001). PRP reduced VAS by 57% (30.0 ± 11.0 mm), WOMAC by 42% (35.0 ± 7.5), DASH by 38% (40.0 ± 9.5), and thickness by 45% (1.54 ± 0.30 mm) at 1 month; by 3 months, VAS was 20.0 ± 9.0 mm, WOMAC 25.0 ± 6.5, DASH 30.0 ± 7.5, thickness 1.40 ± 0.28 mm (p < 0.001). Saline reduced VAS by 30% (50.0 ± 14.0 mm), WOMAC by 26% (45.0 ± 9.5), DASH by 24% (50.0 ± 10.5), thickness by 30% (1.99 ± 0.38 mm) at 1 month; by 3 months, VAS was 40.0 ± 11.0 mm, WOMAC 40.0 ± 8.5, DASH 45.0 ± 9.5, thickness 1.85 ± 0.35 mm (p < 0.01). PRP outperformed saline (p < 0.001). Adverse events were mild (15% PRP, 7% saline).
conclusionsNon-activated PRP induces time-specific growth factor release, outperforming saline in 3-month pain, function, and tendon thickness outcomes for tenosynovitis. The larger sample size enhances generalizability, aligning with recommendations for robust musculoskeletal trials and refuting claims of PRP equivalence to placebo. These findings guide PRP timing and support its efficacy over placebo. They also underscore the importance of individualized PRP dosing strategies based on platelet concentration thresholds.
trial registrationIn the Pan African Clinical Trials Registry (PACTR202506613254896) on 10 June 2025, and is accessible at: https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=34788 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.